Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer


Rani Bansal, Julie McGrath, Phillip Walker, Matias A Bustos, Estelamari Rodriguez, Sarah L. Sammons, Melissa K. Accordino, Jane Meisel, Margaret E. Gatti-Mays, Emily Hsu, Kate Lathrop, Virginia Kaklamani, Matthew Oberley, Michael W. Korn, Stephanie L. Graff

Key Findings:

  • With some exceptions, HER2-Low (H2L) breast cancer shares genomic features with its more classically defined subset of either HR+ or HR- disease.
  • Notable differences in PIK3CA (an actionable mutation) and TP53 (a prognostic alteration) warrant additional assessment, as do amplifications variable between HR+H2L and HR+HER2-positive groups.
Download Publication